Are there any related-party or family relationships for the new Shuttle Pharmaceuticals directors?

The company stated there are no family relationships between Mr. Pathigoda or Mr. Liriano and any existing directors or executive officers, and that neither has any direct or indirect material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Shuttle Pharmaceuticals (SHPH) adds two directors and reshapes key committees

Q: What board changes did Shuttle Pharmaceuticals (SHPH) disclose?

Shuttle Pharmaceuticals disclosed the appointment of Sachin Pathigoda and Angel Liriano as directors, along with new committee chair and membership assignments for them and the designation of George Scorsis as Chairman of the Audit Committee.

Q: What roles will Sachin Pathigoda hold at Shuttle Pharmaceuticals (SHPH)?

Sachin Pathigoda was appointed as a director on September 12, 2025 . Effective September 15, 2025, he became Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee .

Q: What roles will Angel Liriano hold at Shuttle Pharmaceuticals (SHPH)?

Angel Liriano was appointed as a director on September 12, 2025 . On September 15, 2025, he became Chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee .

Q: Did Shuttle Pharmaceuticals (SHPH) change leadership of its Audit Committee?

Yes. The company appointed director George Scorsis as Chairman of the Audit Committee , while also adding Sachin Pathigoda as an Audit Committee member.

Q: Were there special arrangements behind the appointment of the new Shuttle Pharmaceuticals (SHPH) directors?

The company reported there were no arrangements or understandings by which Mr. Pathigoda and Mr. Liriano were appointed as directors.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. reported changes to its board leadership. On September 12, 2025, Sachin Pathigoda and Angel Liriano were appointed as directors. On September 15, 2025, Mr. Pathigoda became Chairman of the Nominating and Corporate Governance Committee and joined the Audit Committee, while Mr. Liriano became Chairman of the Compensation Committee and joined the Nominating and Corporate Governance Committee. The company also named existing director George Scorsis as Chairman of the Audit Committee. The filing notes there are no family relationships with current directors or executive officers, no related-party transactions requiring disclosure, and no special arrangements or understandings behind the new director appointments.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Understanding 8-K Material Events →

09/18/2025 - 05:11 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 12, 2025

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41488

82-5089826

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.00001 per share		SHPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 12, 2025, Sachin Pathigoda and Angel Liriano were appointed as directors of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”). On September 15, 2025, Mr. Pathigoda was also appointed as the Chairman of the Nominating and Corporate Governance Committee and Mr. Liriano was appointed as the Chairman of the Compensation Committee. In addition, Mr. Pathigoda was appointed as a member of the Audit Committee and Mr. Liriano was appointed as a member of the Nominating and Corporate Governance Committee.

In addition, George Scorsis, a director of the Company, was appointed as Chairman of the Audit Committee.

There are no family relationships between Mr. Pathigoda or Mr. Liriano and any of the Company’s directors or executive officers. Neither Mr. Pathigoda nor Mr. Liriano have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Mr. Pathigoda and Mr. Liriano were appointed as directors of the Company..

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Dated: September 18, 2025
	By:	/s/ Christopher Cooper
	Name:	Christopher Cooper
	Title:	Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What board changes did Shuttle Pharmaceuticals (SHPH) disclose?

Shuttle Pharmaceuticals disclosed the appointment of Sachin Pathigoda and Angel Liriano as directors, along with new committee chair and membership assignments for them and the designation of George Scorsis as Chairman of the Audit Committee.

What roles will Sachin Pathigoda hold at Shuttle Pharmaceuticals (SHPH)?

Sachin Pathigoda was appointed as a director on September 12, 2025. Effective September 15, 2025, he became Chairman of the Nominating and Corporate Governance Committee and a member of the Audit Committee.

What roles will Angel Liriano hold at Shuttle Pharmaceuticals (SHPH)?

Angel Liriano was appointed as a director on September 12, 2025. On September 15, 2025, he became Chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.

Did Shuttle Pharmaceuticals (SHPH) change leadership of its Audit Committee?

Yes. The company appointed director George Scorsis as Chairman of the Audit Committee, while also adding Sachin Pathigoda as an Audit Committee member.

Were there special arrangements behind the appointment of the new Shuttle Pharmaceuticals (SHPH) directors?

The company reported there were no arrangements or understandings by which Mr. Pathigoda and Mr. Liriano were appointed as directors.